v
accin
viral
diseasehav
trad
ition
reli
attenu
viru
strain
inactiv
infecti
viru
subunit
vaccinesbas
viral
protein
expressedin
heterolog
systemshav
effectivefor
pathogen
ofien
suffer
poor
immunogen
due
incorrect
protein
fold
modif
chapter
focu
specif
classofvir
subunit
vaccin
mimic
overal
structur
ofviru
particl
thu
preserv
nativ
antigen
conform
ofth
immunogen
protein
theseviruslikeparticl
vlp
produc
wide
rang
taxonom
structur
distinct
virus
uniqu
advantag
term
safeti
immunogen
previou
approach
new
vlp
vaccin
papillomaviru
begin
reach
market
placew
argu
technolog
comeofag
must
consid
viabl
vaccin
strategi
mani
infectiousvirus
remain
major
threat
public
health
seetabl
effect
vaccin
exist
vaccin
usual
costeffect
longterm
protect
diseaseand
spread
virusesth
principl
ofvaccin
gener
suffici
immun
protect
infecti
diseas
thu
vaccin
stimul
bodi
natur
defensesagainst
diseas
use
benign
decoy
mimic
virul
pathogen
similar
vaccin
natur
diseas
better
immun
respons
pathogen
subsequ
exposur
gener
resist
viru
infect
depend
develop
ofan
immun
respons
antigen
present
surfac
ofvirion
virusinfect
cell
therefor
identif
ofprotect
antigen
first
step
develop
ofeffectivevir
vaccin
current
mani
successfulvir
vaccin
develop
use
vaccin
predominantli
base
live
attenu
inactiv
virus
live
attenu
vaccin
measl
mump
rubella
oral
polio
smallpox
varicella
yellow
fever
weaken
form
ofth
wild
virus
attenu
viru
vaccin
reli
limit
replic
ofth
viru
host
follow
vaccin
immun
respons
induc
similar
natur
infect
often
vaccin
effect
singl
dose
howev
vaccin
may
caus
sever
reaction
patient
ofien
result
ofth
limit
replic
ofth
att
enuat
viru
follow
vaccin
contrast
attenu
live
viru
vaccin
inactiv
kill
vaccin
replic
genet
materi
overal
structur
purpos
destroy
vaccin
safer
live
vaccin
gener
effect
thesevaccin
madeaswhol
cellvaccin
suchasinfluenza
polio
rabiesand
hepatitisa
asfractionalor
subunit
vaccin
ashepatitisb
subunit
vaccin
basedon
deliveri
limit
number
viral
protein
often
major
protein
capsidor
envelop
suffici
conferprotectiveimmun
thesevaccin
arean
incrementalstep
saferthan
inactiv
vaccin
becausesubunit
vaccin
prepar
independ
cultur
replic
viru
inde
remain
possibilityof
incomplet
inactiv
batch
batch
variat
safetyof
vaccinei
elimin
howev
subunit
vaccin
havetradit
suffer
one
import
drawback
often
singleprotein
express
purifi
absenc
ofoth
viral
componentsar
less
immunogenicthan
areincorpor
infecti
virusthisisprobablybecaus
proport
protein
ispresentin
misfoldedconform
rel
nativeprotein
thu
doseswith
higher
amount
antigen
requir
achieveth
samelevel
ofprotect
majoradv
subunit
immunogenproduct
hasbeen
assembl
ofproteinsasviruslik
particl
vlp
usingprotein
express
technologyin
yeast
insect
mammalian
cell
vlp
highli
effect
type
subunit
vaccin
mimic
overallstructur
viru
particl
without
requir
contain
infectiousgeneticmateri
inde
manyvlpslack
dna
rna
genom
viru
altogeth
haveth
authent
conform
viral
capsidprotein
seenwith
attenu
virusvaccin
without
anyof
risksassoci
viru
replic
inactiv
vlp
prepar
base
observ
express
capsid
protein
manyvirus
leadsto
spontaneousassembl
ofparticlesthat
arestructurallysimilarto
authent
viru
practicalterm
fact
vlpsmimic
structur
virusparticlesusu
mean
vlpsshouldelicitstronghumoralrespons
lowerdos
antigenrel
subunit
vaccin
aresuffici
elicitsimilarprotectiverespons
addit
abilityto
stimul
b
cell
mediat
immun
respons
vlpshavealso
demonstr
highli
effect
prolif
ctl
responsesl
thisfeatureof
vlpvaccin
like
major
contribut
effect
field
also
becomingincreasingli
clear
preciseprimebooststrategi
canb
import
effect
vaccinationisasa
strategyto
control
diseasetherefor
addit
vlpto
arsen
vaccin
strategi
anydiseas
extend
type
ofprimeboostregimethat
beemploy
date
vlp
produc
mani
differentvirus
infect
human
anim
review
one
strikingfeatur
group
extrem
divers
term
structur
individualvirus
includesvirus
havea
singlecapsidprotein
multiplecapsidproteinsand
thosewith
without
lipid
envelop
clearli
allofth
vlp
gener
date
appropri
vaccin
target
vlp
gener
facilit
fundament
understand
viru
assembl
process
morphogenesi
architectur
ofvirus
howev
import
point
remain
structur
target
virion
limit
successofvlp
product
although
variou
express
system
employ
vlp
product
chapter
mainli
focu
insect
cell
cultur
produc
vlp
develop
candid
vaccin
rational
behind
among
express
system
insect
cell
togeth
baculoviru
express
system
appear
one
promis
vlp
technolog
develop
ofvir
vaccin
fig
state
varietyof
protein
express
system
avail
express
recombin
protein
particl
howevercertain
criteriafor
generationofvlp
prophylacticvaccin
particularli
forhumanviralinfect
mustb
consid
orderforavlpto
bearealisticvaccin
candid
need
produc
safeexpress
systemthat
easyto
scaleup
largescal
show
baculoviru
expressedinsect
cellproducedvlpsthat
havebeendemonstr
highlyimmunogenicand
potenti
vaccin
candidatesthisinsectcellbas
protein
product
systemha
manyadvantag
vlp
product
firstli
extrem
largeamount
correctli
fold
recombin
protein
produc
highdens
cellcultur
condit
eukaryot
cell
secondli
baculoviru
express
system
havebeen
developedfor
express
multipl
foreign
protein
simultan
singl
recombin
viru
facilit
capsid
assembl
infectedcel
thirdli
asth
insectcellsthat
usedfor
vaccin
product
cultur
without
need
manunalian
cellderivedsuppl
risksof
cocultur
opportun
istic
pathogen
minim
fourthli
baculoviru
use
recombin
protein
express
narrow
host
rang
includesonli
fewspeci
oflepidopteraand
therefor
repres
threatto
vaccin
individu
final
baculoviru
system
amen
scaleup
largescalevaccin
product
number
ofnonenvelop
virusesvir
capsidsar
form
one
two
major
protein
thu
rel
easyto
manipul
gener
vlpsbyheterologousexpress
system
examplesofthes
vlpsform
expressionofth
major
capsidprotein
papillomavirus
parvovirus
calcivirus
circovirs
polyomavirus
hepat
e
viru
tabl
virus
nonenvelop
singl
virallyencod
protein
form
major
structur
compon
virion
papillomaviru
vlp
among
completelystudi
ofthi
collect
vlp
advancedstagewith
respectto
product
ofa
usefulvaccin
vlp
ofpapillomavirusesar
form
expressionof
major
capsidprotein
lo
particlesar
highli
immunogen
ableto
stimul
humor
cellmedi
immun
responsesp
human
papillomaviru
hpv
isth
lead
causeofcervicalcancerglob
ofal
cervicalcanc
casesareassoci
two
serotypesofhpi
hpvl
vlpsproduc
insect
cellshavebeen
use
success
phase
ii
human
clinicaltri
largenumb
shown
highli
efficaci
moreov
glaxosmithklin
cervicalcancervaccinecandid
cervarix
target
hpv
iscurrentlyundergoingphaseiii
clinicaltrialsinvolvingmor
worldwid
phase
iii
random
doubleblind
trial
conduct
multipl
centr
denmark
estonia
finland
greec
netherland
russian
feder
vaccine
receivedth
hpv
vlp
asfollow
healthygirl
yearsold
young
women
receivedth
candid
vlp
vaccineaccord
month
schedul
antihpv
antibodi
titer
wereassess
month
seven
per
cent
seroposit
wasachievedin
group
hpv
although
averag
antibodi
titer
hpv
typeswereat
leasttwofoldhigh
yearoldgirlsthevaccinewastoler
byallpati
vaccinerel
seriousadverseeffectswer
detect
followupsmdi
clearli
demonstr
sustain
efficaci
vlp
year
conclus
bival
hpv
vaccin
highli
immunogen
safe
induc
high
degre
ofprotect
hpvl
infect
associatedcervicalles
thesestudiesarenot
onlyan
import
demonstrationofth
effect
ofhpvvlp
vaccin
multiserotyp
vlp
effect
also
highlight
fact
insect
cell
produc
vlpsare
realisticalternativeashuman
vaccin
againstviraldiseas
alsob
mention
point
tetraval
vlp
vaccin
guardasil
merk
produc
yeastcellswasapprov
fda
une
use
women
age
vlp
vaccinesfor
variousdiseas
causedbi
parvovirusinfect
alsoat
advancedstag
although
yet
none
undergon
larg
scaletri
report
hpv
synthesi
ofmajor
structur
protein
ofcanin
parvoviru
cpv
porcin
parvoviru
ppv
led
assembl
ofvlp
insect
cell
vaccinationtri
cpv
vlp
dog
ppv
vlp
pigswer
highli
encouragingi
one
efficaci
assaydog
receivedaslittl
vlp
werecompletelyprotect
viru
infect
challengedwith
virul
viru
furthermorea
vlp
adjuv
wasableto
protect
mink
againstchallengewith
antigen
similarviru
mink
enteritisviru
mev
similarlyit
report
recent
singleimmun
porcin
starin
vlp
yield
complet
protect
target
anim
infecti
ppv
strainsp
inde
microgram
dose
ofvlp
gilt
highli
immunogen
alsoveryefficientin
prevent
transplancentalviru
transmiss
significantli
reduc
number
reproduct
failur
addit
feasibilityof
safelargescal
product
porcin
parvovirusvlpvaccin
hasbeen
establishedcomplyingwith
europeanpharmacopoeia
requir
calicivirusstudi
reli
heavilyon
product
protein
heterolog
system
mainli
due
fact
yet
possibl
grow
viru
cell
cultur
thu
vlp
norwalklik
virus
extrem
use
sourc
diagnost
antigen
monitor
diseaseoutbreak
norwalk
viru
vlp
also
shown
effect
stimul
igg
iga
humor
responsesin
mice
vlpsfor
hepat
e
havebeen
assembl
usinga
truncat
form
viruscapsidprotein
immun
studi
mice
vlpswereabl
induc
system
mucosalimmun
respons
follow
oral
adminisrrarionp
furthermor
oral
administr
hepat
e
vlp
cynomologousmonkey
induc
igm
iga
igg
respons
suffici
protect
infect
diseas
challengewith
viru
thu
clear
potenti
applic
thesevlpsa
vaccinefor
hepat
e
vlppreparationsto
circovirus
polyomavirusareat
less
advanc
stagevlp
format
hasbeen
report
circovirusbut
asyetno
seriousattempt
hasbeenmadeat
vaccin
product
vaccin
rabbitswith
vlpsfor
humanjc
virusin
presenceof
adjuvantallowedproduct
ofa
hyperimmuneserumthat
effect
neutralizedinfectiousviruspreparadon
howev
absenceofadjuv
respons
pattern
responsei
unusualfor
vlpsin
gener
often
stimulatestrong
immun
respons
evenin
absenceofadjuvantinde
vlp
murin
polyomaviru
abl
stimul
strong
immun
responsein
absenc
adjuv
administ
singl
ng
dose
intriguingli
particl
appear
particularlystablewith
alter
ofparticl
morpholog
reduct
immunogen
even
weeksstorageat
room
ternperaturep
viral
particl
contain
multipl
interact
capsid
protein
present
technic
challengethan
form
one
two
major
capsidprotein
particularli
far
difficultifth
assembl
protein
capsidsar
encod
multipl
discretemrna
processedfrom
singlepolyprotein
caseof
picornavirus
due
fact
efficientassembl
vlp
interact
capsidprotein
must
express
vicin
word
samecel
assembl
vlpsbyprocessingof
polyprotein
achievedboth
polioviru
infectiousbursaldiseaseviru
usingth
baculoviru
expressionsystem
complex
assembl
multilay
multiprotein
vlp
also
effici
produc
member
reovirida
theseviruseshav
capsidsmad
concentr
layer
differ
capsidprotein
coexpressionin
insect
ofthes
capsid
protein
depend
viru
particl
made
allowedth
product
ofvlp
empti
segment
dsrna
viral
genom
otherwis
indistinguish
authent
viral
particl
first
member
reouirida
vlp
describ
bluetongu
viru
btv
insect
transmit
anim
viru
remain
systemin
familyfor
largestvarietyofdifferentvlpsand
recombin
singleantigen
subunit
immunogen
made
baculoviru
express
system
test
addit
requir
efficientcoexpress
viralcapsidprotein
sameinsect
cellin
systemha
result
develop
ofbaculoviru
multigeneexpress
focuson
system
somedetail
asit
highlightsboth
effect
ofvlp
vaccin
someof
technolog
advanc
havebeen
made
product
ofvlp
complexarchitectur
bluetongu
diseas
affect
mainli
sheep
cattl
classifi
emergingdiseasein
europ
diseas
causedbi
bluetongu
viru
bti
multilay
icosahedr
structur
form
nonequimolar
amount
sevenvir
protein
three
structur
protein
dispens
format
vlpsa
playonli
enzymaticrol
viru
transcript
rnachineryp
remainingfour
structur
protein
organisedin
two
capsid
inner
capsidactsasa
scaffold
assembl
outer
capsidthat
respons
cellentri
henc
contain
major
candid
viru
neutralis
express
four
major
structur
protein
btv
achiev
construc
baculoviru
simultan
express
four
proteinsyth
advantag
approach
coinfect
sever
baculovirus
express
singl
protein
equival
condit
achievedin
infect
cell
thu
assembl
ofvlp
efficientasexpress
j
g
vlp
vlp
control
level
cell
rather
level
cultur
case
mix
infect
btv
vlp
fig
vlp
two
differ
serotyp
combin
vaccina
te
anim
anim
vlp
vaccin
provid
complet
protect
rwo
vaccin
seroryp
also
partial
protect
fromchalleng
relatednonvaccin
serotypesth
protectiveefficaci
ofvaccin
thesetrialsextendedovera
long
month
periodpihi
observationrais
possibilitythat
broad
spectrumvaccin
againstal
btv
serotyp
possibilitybycombiningvlpsfrom
rel
smallnumb
serotyp
btv
system
also
demonstratesth
effici
ofvlp
vaccin
rel
immun
subunit
vaccin
base
dissoci
antigen
unassembl
recombin
antigen
addit
assembl
vlpsthe
two
componentsofth
btv
outer
capsid
alsopreparedand
testedin
vaccin
studieswhil
majorserotypedetermin
antigen
wasonlypartiallyprotectiveforashort
durat
againstvirulentviruschalleng
combin
protect
contrast
contain
affordeda
better
level
protect
much
longer
durat
thesestudi
demonstr
assembl
antigensinto
vlpsresultsin
effect
immunogen
deliveryof
separ
isolatedprotein
addit
btv
vlp
also
produc
rotaviru
anoth
member
reovirida
intriguingli
vlpsformedfrom
twoinner
structuralproteinsaloneof
rotaviru
capsid
shown
effect
immunogen
anim
mice
even
intrarect
immunisationwhich
inducesa
localmucosalrespons
issuffici
protect
rotavitu
infect
v
data
immunogenicityexperi
encouragingand
possibl
rotavirusvlp
mayprovidea
viablealtern
livevitu
vaccin
rotavitu
manypathogenicvirus
suchasinfluenza
hiv
hepatitisc
aresurroundedbyan
envelop
membranethat
consist
lipid
bilayerderivedfrom
host
cell
insertedwith
vitusglycoprotein
spike
theseprotein
targetsofneutralizingantibodiesand
areessenti
compon
ofvaccin
due
inher
properti
lipid
envelop
assembl
ofvlp
insect
cellsfor
thesevitusesi
differ
type
oftechnicalchalleng
produc
vituseswith
multipl
capsid
nevertheless
effici
format
ofvlp
number
envelop
virus
insectcel
hasbeen
reportedforexampl
vlpsof
hepatitisc
viru
sever
retrovirus
sarscoronaviru
influenza
havedemonstratedcorrectassemblyof
lipidenvelop
theglycoprotein
insertedsoss
inde
retrovirus
hasbeenposs
producehybridvlpsthat
contain
gagcapsidprotein
fromon
viru
siv
envelopeprotein
anoth
hiv
insect
cell
although
none
retroviru
derivedvlpsar
yet
stagethat
beingusedin
clinicalvaccinetri
initi
experi
anitnalmodelsar
promis
vlp
sar
coronavitu
basisfor
vaccinationwer
produc
rapidlyfollow
sarsoutbreak
howeverth
control
ofsar
coronavirusbyepidemiolog
measur
continu
lackof
reemerg
viru
difficulti
workingdirectlywith
viru
havesever
limit
developmentof
sarsvlp
vaccin
despit
antiserum
raisedin
mice
againstinsect
cellderivedsarsvlpswereableto
neutralizea
retroviruspseudotyp
sarss
protein
hepat
c
vlp
fig
havebeen
test
miceand
baboonsand
shown
effect
stimulatingboth
cellularand
humoralimmun
respons
one
experi
weekold
femal
balblc
micewer
immunizedintramuscularli
three
time
three
week
intervalswith
cellderivedh
cv
vlp
produc
bycoexpress
hcv
lackofasuitableanimalmodelfor
h
cv
infectionsa
recombinantvaccinia
vitusexpress
hcv
structur
protein
vvhcv
wasusedasa
modelsystem
vaccin
micewerechalleng
three
daysafterth
finalimmunizationwithvvhcv
five
dayslaterth
ovari
ofinfectedmic
wereharvest
vaccinia
virustitr
determin
fiveout
ofseven
vaccinatedanimalshad
detectablevacciniaviru
ovari
point
remainingtwo
anitnalshad
five
log
lowervacciniatitr
compar
control
mice
addit
studi
wasabl
demonstr
vlpsefficaci
wasbasedlarg
stimul
tcell
respons
studi
baboonsha
demonstr
vlpsare
welltoler
stimul
broad
longlastinghcv
target
immun
responsesp
b
figur
summari
product
test
vlp
sar
coronaviru
left
cartoon
right
electron
micrograph
vlp
produc
coexpress
e
protein
sar
coronaviru
vlp
use
rais
antisera
mice
abil
antisera
protect
infect
sar
protein
pseudotyp
lentiviru
assess
b
neutralis
antibodi
dilut
sar
pseudotyp
lentiv
iru
use
sera
mice
immun
ize
sar
vlp
rotaviru
vlp
serum
obtain
sar
convalesc
patient
date
structur
complic
envelop
viru
particl
use
gener
vlp
influenzavlp
influenzaa
produc
groupspthes
studi
shown
express
major
structur
protein
mi
alon
suffici
result
bud
ofviruslikevesicl
insect
cell
also
coexpressionofml
ha
na
leadsto
assembl
influenzavlp
miha
mihana
vlp
confer
protect
lethal
challengewith
type
influenza
mice
vlp
product
also
success
achiev
coexpress
ha
na
mi
influenza
viru
use
singl
recombin
baculovirusp
date
none
ofthes
influenza
vlp
havebeen
test
human
howev
potenti
ha
na
could
incorpor
directli
vlp
circul
influenza
strain
without
passag
tissu
cultur
particular
advantag
control
rapidli
chang
influenzaa
viru
addit
use
ofvlp
direct
immunogen
effici
stimul
cellular
humor
respons
made
prime
candid
carrier
moleculesfor
deliveryof
epieop
dna
smallmolecul
targetingoth
diseas
thisha
facilit
excel
structur
inform
often
avail
viru
particlesallowingr
designof
vaccin
epitop
exposedon
surfaceof
vlp
manyof
vlpsthat
developeda
vaccin
right
also
test
deliveri
system
molecul
possibl
providea
full
accountof
approach
literatur
deliveryand
display
usingvlpsi
leastaslargea
vlp
product
direct
immun
reviewseeref
howeverit
necessari
least
introduc
import
area
ofvlpbas
vaccin
developmentth
use
ofvlp
carrier
molecul
epitop
diseas
isnot
limit
thosevlpsthat
areform
capsid
econom
signific
virus
reasonthat
manyvlpsmakeexcel
carriermolecul
deliveri
epitop
vaccin
like
particul
vlp
structur
readili
taken
antigen
present
cell
thu
abl
prime
long
last
ctl
respons
addit
antibodi
respons
one
approach
mayb
use
overcom
constraint
would
link
foreign
protein
sequenc
capsidprotein
way
extend
n
c
termini
protein
extendeith
insideor
outsid
particl
ofcours
isonli
suitablewhereon
termini
ofth
protein
exposedon
insideor
outsid
faceof
capsid
far
vlp
awareof
havefullyexploitedth
potenti
approach
success
employedfor
proteinbasedparticul
structur
similar
vlp
stimul
bcell
tcell
respons
requir
complexproteinprotein
interact
particleassembl
despit
accumulatedevid
potenti
ofvlp
potent
immunogensfor
mani
viralsystem
wehavediscuss
thereremain
someresist
vlpapproachasagener
vaccinationstrategyfor
diseas
causedbi
virus
part
due
high
profiledisappoint
resultsfor
vlp
vaccin
earlystag
develop
exampl
ineffect
earlyvaccin
hiv
basedon
thisexamplerais
point
caution
vlpvaccin
design
gener
vlp
stimul
effici
cellular
humor
immun
respons
anyvaccin
relyon
long
term
host
respons
effect
vlpsdesignedto
work
immunocompromisedindividu
need
overcom
samechalleng
effici
immun
responsea
vaccin
approach
notion
vlpsare
ineffect
vaccin
clearli
myth
isexplodedbi
immin
releas
two
new
vlpbase
hpv
vaccin
inde
accumulateddata
fieldsuggest
vlpsare
effect
thanmanyoth
type
subunit
vaccin
becausethey
conform
authent
saferthanmanyl
viruspreparationsbecaus
usual
freeof
viralgeneticmaterialvlpproduct
doesnot
appear
limit
anyon
type
viru
virusfamili
significantli
limit
complexityofth
viru
particl
use
insect
cell
protein
express
system
offer
excitingopportun
synthesi
conform
authent
vlp
form
intracellularassembl
ofmultipl
protein
express
samecel
advantag
system
overoth
use
protein
express
capacityfor
industri
scale
synthesi
largeand
multipl
protein
fact
insectcel
natur
replicationreservoirfor
manypathogenicvirus
thusth
basiccellularmachinerythat
normallyprocess
infectiousform
virusispres
within
express
system
avail
produc
authent
vlp
